November 2, 2011European Journal of Endocrinology
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up
Key result
A high-dose mitotane strategy enabled therapeutic plasma levels (>14 mg/l) to be reached within 1 month in 27% of patients with adrenocortical carcinoma.
Why the study?
Does a high-dose mitotane strategy achieve therapeutic plasma levels and acceptable tolerance in patients with adrenocortical carcinoma?
Population
22 patients with adrenocortical carcinoma (ACC)
Design
Cohort
Follow-up
3 months
Authors
Discussion
Loading...
Member takes
Implication
High-dose mitotane may accelerate therapeutic levels in adrenocortical carcinoma; leaves open impact on outcomes versus standard titration.
Study Design
Type
Cohort (n=22)
Multicenter
No
Structured PICO
Does a high-dose mitotane strategy achieve therapeutic plasma levels and acceptable tolerance in patients with adrenocortical carcinoma?
P
Population
22 patients with adrenocortical carcinoma prospectively enrolled and followed for 3 months to evaluate a high-dose mitotane strategy.
E
Exposure
High-dose mitotane strategy (≥4 g/day, median 6 g/day within 2 weeks, maintenance over 4 weeks)
O
Outcome
Percentage of patients achieving a plasma mitotane level above 14 mg/l and tolerance of mitotane within the first 3 months of treatmentsurrogate
A high-dose mitotane strategy enables therapeutic plasma levels to be reached within 1 month in 27% of patients with adrenocortical carcinoma, with acceptable toxicity.
Cite This Study
Leboulleux et al. (2011) conducted a cohort in adrenocortical carcinoma (n=22). High-dose mitotane strategy was evaluated on Achievement of a plasma mitotane level above 14 mg/l. A high-dose mitotane strategy enabled therapeutic plasma levels (>14 mg/l) to be reached within 1 month in 27% of patients with adrenocortical carcinoma.